[Comparison of methods for evaluating the nephrotoxicity of cisplatin].
The BUN, serum creatinine, creatinine clearance and the urinary excretion of leucine aminopeptidase (LAP), alkaline phosphatase (ALP), beta 2-microglobulin (beta-m), and N-acetyl-beta-glucosaminidase (NAG), were measured in 21 gynecological cancer patients treated with CAPF (CPA + ADM + CDDP + 5-FU) to evaluate the sensitivity of these indices to renal tubular damage. After receiving CDDP almost all patients displayed an increase in excretion of beta-m but no urinary enzyme activities. However, NAG index (NAG activity/urinary creatinine) rose markedly in all patients. We concluded that NAG index is a valuable method in providing sensitive indices for detecting renal tubular damage caused by CDDP.
D000118:Acetylglucosaminidase / Q000652:urine; D000469:Alkaline Phosphatase / Q000652:urine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000009:adverse effects*; D003404:Creatinine / Q000652:urine; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests / Q000379:methods*; D007931:Leucyl Aminopeptidase / Q000652:urine; D001613:beta 2-Microglobulin / Q000652:urine
D001613:beta 2-Microglobulin; D003404:Creatinine; D000469:Alkaline Phosphatase; D000118:Acetylglucosaminidase; D007931:Leucyl Aminopeptidase; D002945:Cisplatin